Trials / Unknown
UnknownNCT04115618
SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma
Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic Esophageal Squamous Cell Carcinoma: a Phase II Study of Single Institution
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to predict the toxicity and efficacy of Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic I-IVA Esophageal Squamous Cell Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Simultaneous integrated boost intensity-modulated chemoradiotherapy | Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw. |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
- First posted
- 2019-10-04
- Last updated
- 2019-10-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04115618. Inclusion in this directory is not an endorsement.